PSK Pharma’s line of drugs to prevent acute and delayed chemotherapy-induced nausea and vomiting caused by chemotherapy has increased: the company has received a registration certificate for the second drug of this group, Aprepitant PSK”, the company said in its statement.
Aprepitant PSK capsules are available in dosages of 80 and 125 mg. Earlier, the company registered Phosaprepitant PSK, Russia’s first infusion phosaprepitant for complex chemotherapy used to prevent acute and delayed nausea and vomiting caused by highly or moderately emetogenic antitumor chemotherapy.
“Chemotherapy frequently leads to nausea and vomiting, so the attending physician always tries to offer antiemetic drugs to the patients who are administered chemotherapy. And our task, as a responsible domestic manufacturer, is to offer both the patient and the doctor the widest possible range of products that will be effective, accessible and comfortable for the patient,” Evgenia Shapiro, General Director of PSK Pharma, explains the expansion of the line of oncology therapies.
